Study on Delayed Graft Function Using Paired Kidneys
Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maastricht
-
Minderbroedersberg, Maastricht, Netherlands, 6211 LK
- Maastricht University Medical Center
-
-
-
-
Madrid
-
San Carlos, Madrid, Spain, 28001
- Hospital Clinico San Carlos
-
-
-
-
metropolitan county of Tyne and Wear
-
Newcastle, metropolitan county of Tyne and Wear, United Kingdom, NE7 7DN
- The Newcastle Upon Tyne Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subjects must sign the informed consent document prior to performance of any study related procedure including the Screening procedure.
- Males and females ≥ 18 years of age.
- Had renal transplantation due to end stage disease requiring chronic dialysis.
- Study drug can be administered within 6 to 36 hours after transplantation.
- Received kidney from donor after cardiac death.
- DCD kidney fulfills the clinical site's criteria for transplantation.
- Creatinine clearance from the transplanted kidney over a 2-hour collection period is <10 mL/min, OR no urine output OR average urine output of < 50 cc/H over 8 or more consecutive hours,, OR normal urine output following transplantation that diminished to average of < 50 cc/H over 8 or more consecutive hours, OR Creatinine reduction ratio 24 hours after transplantation to pre-transplantation is < 30%.
- Dry weight ≤ 100 kg.
- Women of child bearing potential have a negative pregnancy test prior to transplantation.
- Women of child bearing potential (including perimenopausal women who have had a menstrual period within 1 year) must agree to use 2 forms of effective birth control regimen (at least one-barrier method) during the 28-day study period. Men must agree to use condoms during the study period; a condom with spermicide is considered a single barrier.
- In the opinion of the Investigator, the subject is capable of understanding and complying with the protocol.
Exclusion Criteria
- Mean arterial pressure <40 mmHg or cardiac index <1.8 L/min/m2.
- Recipient of multiple organ transplantation or scheduled for multiple organ transplantation.
- Recipient of kidney from a pediatric donor age 10 years or less.
- Recipient age > 75 years.
- Patients with ASA 4 or 5
- Patients with chronic obstructive pulmonary disease (COPD) GOLD IV
- Has measurable donor-specific antibody or positive cross-match requiring deviation from standard immunosuppressive therapy.
- Currently participating in or has participated in an investigational drug or medical device study within 30 days or five half-lives, whichever is longer, prior to enrolment into this study.
- Concurrent sepsis or active bacterial infection.
- Have an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
- Women of child bearing potential who is breast feeding.
- History of positive HIV test.
- History of rheumatoid arthritis.
- History of proliferative retinopathy or laser surgery for retinopathy.
- Subjects who have a penicillin allergy.
- Subjects who require the cytochrome P450 1A2 (CYP1A2) inhibitors, or are receiving ciprofloxacin and fluvoxamine (Luvox®).
- Subject is unwilling or unable to comply with the protocol or to cooperate fully with the Investigator or the site personnel.
- Subject is not deemed medically stable for the study in the opinion of the Investigator or the subject's primary nephrologist.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Normal saline
Placebo
|
Daily intravenous administration for four (4) days.
The volume of normal saline will vary by estimated weight.
|
|
Active Comparator: BB3
Small molecule mimetic of hepatocyte growth factor/scatter factor
|
Daily intravenous administration of 2mg/kg for 4 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
creatinine clearance
Time Frame: 7 days
|
The primary analysis to assess the activity of BB3 compared to placebo will be the mean difference in creatinine clearance over time using selective 24-hour urine collections from the transplanted kidney from the first infusion of study drug through day 7 post-transplant.
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of hospitalization following transplantation
Time Frame: 28 days
|
Length of hospitalization following transplantation
|
28 days
|
|
Urine production
Time Frame: 28 days
|
Median time (days) until production of ≥1 litre urine over a 24-hour period, i.e. median number of days following the first infusion of study drug until the first day (08:00 - 08:00) that urine production was ≥1 litre over a 24-hour period.
|
28 days
|
|
Creatinine clearance
Time Frame: 28 days
|
Calculated creatinine clearance at days 14 and 28
|
28 days
|
|
Incidence of delayed graft function
Time Frame: 7 days
|
Incidence of delayed graft function (required dialysis due to inadequate renal function during the first 7 days after transplantation).
|
7 days
|
|
Number of dialysis sessions
Time Frame: 28 days
|
Number of dialysis sessions through day 7, 14, and 28
|
28 days
|
|
Mean total daily urine output
Time Frame: 14 days
|
Mean total daily urine output through day 14
|
14 days
|
|
Daily serum creatinine
Time Frame: 7 days
|
Daily serum creatinine at days 1 to 7
|
7 days
|
|
Mean serum creatinine
Time Frame: 28 days
|
Mean serum creatinine at days 4, 7, 10, 14, and 28
|
28 days
|
|
Follow-up on graft survival and function
Time Frame: 12 months
|
Results of the 6- and 12-month follow-up on graft survival and function will be summarized as an addendum to the final clinical study report
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 004-09
- 2010-019243-19 (EudraCT Number)
- 2R44DK078455-02 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.